Antitrust Scrutiny Of Patent Listings Could Undo Waxman/Hatch – Attorney
Executive Summary
A recent district court decision regarding Bristol's BuSpar allowing antitrust claims against the company to proceed could undermine Waxman/Hatch by discouraging companies from listing patents in the Orange Book, Ropes & Gray attorney James Spears said
You may also be interested in...
USP Monograph Changes Could Be Strategy To Impede Generic Entry
Modifications to a branded drug's U.S. Pharmacopeia monograph could pose impediments to generic entry, Frommer, Lawrence & Haug attorney Andrew Berdon said
USP Monograph Changes Could Be Strategy To Impede Generic Entry
Modifications to a branded drug's U.S. Pharmacopeia monograph could pose impediments to generic entry, Frommer, Lawrence & Haug attorney Andrew Berdon said
Buspirone Generic Approvals Expected By End Of February After Patent Ruling
FDA is expected to approve additional generics of buspirone by the end of the month following a court ruling throwing out Bristol-Myers Squibb's late-listed BuSpar patent